

KING PHARMACEUTICALS INC

Form 8-K

November 09, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 9, 2005

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

<b>Tennessee</b> (State or other jurisdiction of incorporation)	<b>0-24425</b> (Commission File Number)	<b>54-1684963</b> (I.R.S. Employer Identification No.)
-----------------------------------------------------------------------	--------------------------------------------	-----------------------------------------------------------

**501 Fifth Street, Bristol, Tennessee 37620**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(423) 989-8000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 2.02 Results of Operations and Financial Condition

ITEM 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EX-99.1 PRESS RELEASE 11/09/05

---

**Table of Contents**

**ITEM 2.02 Results of Operations and Financial Condition.**

On November 9, 2005, King Pharmaceuticals, Inc. announced its consolidated financial results for the three and nine months ended September 30, 2005. A copy of the press release issued in connection with the announcement is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

**ITEM 9.01 Financial Statements and Exhibits.**

(c) Exhibits

Exhibit

Number	Description
--------	-------------

99.1	Press release issued by King Pharmaceuticals, Inc. dated November 9, 2005.
------	----------------------------------------------------------------------------

The material being furnished pursuant to Item 2.02 of this Current Report on Form 8-K shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**King Pharmaceuticals, Inc.**

By: /s/ Brian A. Markison

Brian A. Markison  
President and Chief Executive Officer

Date: November 9, 2005

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press release issued by King Pharmaceuticals, Inc. dated November 9, 2005.